We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.00 | -0.35% | 1,435.00 | 1,454.00 | 1,456.00 | 1,474.00 | 1,437.00 | 1,440.00 | 355,661 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 982.43 | 1.97B |
From May 2019 to May 2024
TIDMINDV
RNS Number : 3892G
Indivior PLC
06 November 2018
Indivior Announces Upcoming Investor Events
Slough, UK, and Richmond, VA, 6 November 2018 - Indivior PLC (LON: INDV) today announced the following upcoming investor events:
Stifel 2018 Healthcare Conference, New York City:
On Tuesday, November 13th from 9:30 a.m. to 10:10 a.m. (local time) Shaun Thaxter, CEO, and Mark Crossley, CFO, will conduct a fireside chat with Max Hermann, Stifel Healthcare Analyst.
Indivior 2018 Capital Markets Day, New York City:
On Wednesday, December 5th from 9:00 a.m. to 12:30 p.m. (local time), Indivior senior management will review and present the Company's key business lines. Attendance for this event will require pre-registration, as space is limited. To register, please send an e-mail to jason.thompson@indivior.com.
A live webcast of both events, including any presentations, will be available on the "Investors" section of the company's website at www.indivior.com.
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-379-1033 or jason.thompson@indivior.com
###
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCZELFBVFFEFBD
(END) Dow Jones Newswires
November 06, 2018 02:00 ET (07:00 GMT)
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
